- SEK20.31bn
- SEK21.21bn
- SEK3.61bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 33.31 | ||
| PEG Ratio (f) | 2.7 | ||
| EPS Growth (f) | 14.07% | ||
| Dividend Yield (f) | 0.83% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.55 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 35.27 | ||
| Price to Sales | 5.63 | ||
| EV to EBITDA | 17.52 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.79% | ||
| Return on Equity | 3.78% | ||
| Operating Margin | 21.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 1,245.57 | 1,680.8 | 3,234 | 3,512 | 3,609 | 3,677.17 | 3,982.17 | 19.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -26.88 | +40.48 | -16.26 | n/a | n/a | +9.15 | +23.76 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Directors
- Jon Sigurdsson CHM (65)
- Thomas Axelsson PRE (62)
- Mikael Engblom CFO (42)
- Fredrik Mattsson SVP (49)
- Claus Bisgaard SVP (44)
- Rickard Ericsson SVP (50)
- Mark Larman CSO (47)
- Karin Russberg SVP (52)
- Maria Forss SVP (49)
- Henrik Blomquist IND (49)
- Lars Holmqvist IND (60)
- Vesa Koskinen IND
- Pia Marions IND (57)
- Karen Sorensen IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 2nd, 1989
- Public Since
- June 26th, 2001
- No. of Shareholders
- 14,724
- No. of Employees
- 1,150
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 135,422,622
- Address
- Gustaf Werners gata 2, Vastra Frolunda, GOETEBORG, 421 32
- Web
- https://www.vitrolife.com/
- Phone
- +46 317218000
- Contact
- Amelie Wilson
- Auditors
- Deloitte AB
Upcoming Events for VITR
Dividend For VITR.ST - 1.1000 SEK
Dividend For VTRLY.PK - 0.0995 USD
Q2 2025 Vitrolife AB Earnings Release
Q3 2025 Vitrolife AB Earnings Release
Similar to VITR
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arcoma AB
OMX Nordic Exchange Stockholm
FAQ
What is the Vitrolife AB share price?
As of Today at 24:01 UTC, shares in Vitrolife AB are trading at SEK150.00. This share price information is delayed by 15 minutes.
How has the Vitrolife AB share price performed this year?
Shares in Vitrolife AB last closed at SEK150.00 and the price had moved by -4.82% over the past 365 days. In terms of relative price strength the Vitrolife AB share price has underperformed the FTSE Global All Cap Index by -7.2% over the past year.
What are the analyst and broker recommendations for Vitrolife AB?
The overall consensus recommendation for Vitrolife AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vitrolife AB dividend yield?
The Vitrolife AB dividend yield is 0.73% based on the trailing twelve month period.
Does Vitrolife AB pay a dividend?
Last year, Vitrolife AB paid a total dividend of SEK1.10, and it currently has a trailing dividend yield of 0.73%.Looking ahead, shares in Vitrolife AB are due to go ex-dividend on 2025-04-30 and the next dividend pay date is 2025-05-07.
When does Vitrolife AB next pay dividends?
Vitrolife AB are due to go ex-dividend on 2025-04-30 and the next dividend pay date is 2025-05-07. The historic dividend yield on Vitrolife AB shares is currently 0.73%.
How do I buy Vitrolife AB shares?
To buy shares in Vitrolife AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vitrolife AB?
As of the previous close price of SEK150.00, shares in Vitrolife AB had a market capitalisation of SEK20.31bn.
Where are Vitrolife AB shares listed?
Here are the trading details for Vitrolife AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: VITR
What kind of share is Vitrolife AB?
Based on an overall assessment of its quality, value and momentum Vitrolife AB is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vitrolife AB share price forecast for 2025?
The analyst consensus target price for shares in Vitrolife AB is SEK226.17. That is 50.78% above the last closing price of SEK150.00.
Analysts covering Vitrolife AB currently have a consensus Earnings Per Share (EPS) forecast of SEK4.19 for the next financial year.
Find out moreWhat is the trend in the Vitrolife AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitrolife AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -36.31%.
As of the last closing price of SEK150.00, shares in Vitrolife AB were trading -29.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vitrolife AB PE Ratio?
The Vitrolife AB PE ratio based on its reported earnings over the past 12 months is 33.31. The shares last closed at SEK150.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vitrolife AB?
Vitrolife AB's management team is headed by:
- Jon Sigurdsson - CHM
- Thomas Axelsson - PRE
- Mikael Engblom - CFO
- Fredrik Mattsson - SVP
- Claus Bisgaard - SVP
- Rickard Ericsson - SVP
- Mark Larman - CSO
- Karin Russberg - SVP
- Maria Forss - SVP
- Henrik Blomquist - IND
- Lars Holmqvist - IND
- Vesa Koskinen - IND
- Pia Marions - IND
- Karen Sorensen - IND